Drug intelligence / Profile preview

POx-Man nanovaccine

Development stage: Preclinical
Lead developer: Tel Aviv University
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

POx-Man nanovaccine is a preclinical, mannose-decorated polyoxazoline-poly(lactic-co-glycolic acid) nanoparticle cancer vaccine developed by researchers at Universidade de Lisboa and Tel Aviv University. The approximately 200 nm formulation co-delivers tumor peptide antigens, immune adjuvants, and regulators of transforming growth factor beta expression. Mannose surface functionalization is intended to target the mannose receptor on dendritic cells, improving antigen delivery and induction of antigen-specific, CD8-positive T-cell-mediated antitumor immunity. In mouse colorectal cancer and melanoma models, POx-Man nanovaccines inhibited tumor growth and enhanced the activity of pexidartinib plus PD-1 blockade; these co-administered agents are not intrinsic components of the POx-Man nanovaccine.

Other names: POx-Mannose nanovaccine

Targets

MRC1 (Mannose Receptor C-type 1)

Beyond the preview

Go deeper on POx-Man nanovaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on POx-Man nanovaccine.

Explore the full profile